Flex Databases Launches New Web Site
News Mar 25, 2014
Flex Databases has announced the launch of a new web site.
The new website cements the company's unique positioning as a PSA company with expertise and product created for the healthcare industry.
The website features graphical representation of a value chain of a contract research organization (CRO) and a healthcare company.
Screenshots are provided, illustrating how the Flex platform can be applied at each of the value building stages and outlining the difference between the set-up of a service organization and a pharma company.
The structure of the site has been simplified and updated to include the latest info on the Flex technology, core team, products and pricing.
"Our new website is the last logical step in defining the story of our company", says Olga Loginovskaya, BD & Marketing Director at Flex Databases. "It will become an invaluable tool in quickly and easily illustrating the profound difference which exists between Flex and other players in the clinical development technology market. We took a step back from the usual acronyms the industry has been conditioned to recognize (TMF, LMS, CRM, CTMS, EDC, etc.) and showed how our system can be used as a complete platform for an organization, starting from the very first steps (people and projects).
This an important milestone, opening the next page in our company history and introducing us to the industry as a pioneer company, with a clear, concise message - the platform is coming."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE